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Background 
Equilibrium between activation and inhibition of immune responses is vital for effective immune 
response that targets foreign particles or antigens, but not on self-antigens. Inhibitory receptors 
expressed on various immune cells are important checkpoints to regulate immune tolerance by 
implementing thresholds for activation signals in immune response. The loss of counterbalancing 
inhibitory effects could contribute to failure of limiting or terminating activation signals, thus leading 
to allergic reactions and autoimmune diseases such as SLE (systemic lupus erythematosus). For 
instance, polymorphism of FCGR2B that encodes inhibitory receptor FcγRIIB is found in SLE 
patients and lupus-prone mice. Paradoxically, leukocyte immunoglobulin-like receptor (LILR) B4, an 
inhibitory member of the human LILR family, has augmented expression on the autoantibody-
producing plasmablasts/plasma cells of SLE patients. The murine counterpart of human LILRB4 is 
reported to be glycoprotein 49B (gp49B), an inhibitory receptor belonging to the immunoglobulin (Ig) 
superfamily. gp49B is expressed on myeloid cells (the most common), activated T cells and natural 
killer cells, marginal zone B cells and memory B cells. However, differ from plasmablasts/plasma 
cells of healthy individual, gp49B is not expressed on plasma cells of wild type mouse strain C57BL/6. 
The purpose of this study is to clarify if gp49B is expressed on plasma cells of lupus-prone mice, and 
if so, to further understand the relationship of LILRB4 with SLE disease, by using genetically 
modified lupus-prone mouse models.  
 
Methodology 
C57BL/6 (B6) mice are wild type mice used as healthy control. Representative lupus-prone mice used 
are BXSB/Yaa and FcgRIIB-deficient mice constructed with the B6 background excepting 129-
derived SLAM locus (RIIB−⁄−SLAM129). gp49B-deficient BXSB/Yaa and RIIB−⁄−SLAM129 mice were 
generated. Flow cytometry analysis was carried out to determine the expression levels of surface 
markers on various immune cells. Plasmablasts/plasma cells were gated as B220low/−CD138high. Anti-
dsDNA (anti-double-stranded DNA) antibodies in the serum were detected by ELISA. Pathology of 
kidney was examined by histological staining with HE and PAS.  
 
Results 
gp49B is expressed on plasma cells of several lupus-prone mice (BXSB/Yaa, MRL/lpr, NZBW F1, 
RIIB−⁄−SLAM129), but not of healthy B6 mouse. The expression level of gp49B is positively correlated 
to the serum titer of anti-dsDNA IgG in BXSB/Yaa mice and is related the onset of autoimmune 
disease in BXSB/Yaa and RIIB−⁄−SLAM129 female mice. Genetic deletion of gp49B decreases but 
does not abolish anti-dsDNA IgG in BXSB/Yaa and RIIB−⁄−SLAM129 female mice. Prolonged survival 
rate and mild kidney inflammation are observed in gp49B-knockout BXSB/Yaa mice, accompanied 
with improvements of disease phenotype in BXSB/Yaa mice (regain of depleted marginal zone B cells 
and slight reduction of monocytosis). On the other hand, gp49B deficiency in aged RIIB−⁄−SLAM129 
mice shows heightened autoimmunity, with lesser longevity and increase of switched memory B cells. 
 
Discussion 
The expression of gp49B on plasma cells of BXSB/Yaa mice could indicate the disease severity 
because its expression that peaks around 15- till 20-week old has similar pattern of changes in serum 
titer of IL-6, anti-nuclear antibody and anti-dsDNA antibodies as reported. Presence of anti-dsDNA 
IgG has been reported to induce glomerulonephritis even in healthy mice. Deletion of gp49B in 
BXSB/Yaa mice results in reduced anti-dsDNA IgG, which then could lead to ameliorated nephritis. 
Less severe glomerulonephritis thus improves the survival rate of gp49B-deficient BXSB/Yaa mice, 
as the major cause of mortality in BXSB/Yaa mice is the result from the development of immune 
complex-mediated glomerulonephritis.  
 
Contradict to BXSB/Yaa mice, gp49B deficiency in RIIB−⁄−SLAM129 female mice only reduces serum 
titer of anti-dsDNA IgG at around 36-week old that marks the onset of autoimmunity, but not so 
profoundly at the later ages. These mice showed a mild reduction of survival rate at very old age (50 
weeks old onwards). Increase frequency of IgM− memory B cells observed in gp49B-deficient 
RIIB−⁄−SLAM129 female mice could be the main cause, as SLE patients in the chronic state have more 
switched memory B cells.  
 
Difference of effects of gp49B deletion noted between BXSB/Yaa and RIIB−⁄−SLAM129 mice showed 
that variations still exist. One possibility could be from the effect of FcγRIIB deficiency, although 
BXSB/Yaa mice and other SLE-prone mouse strains showed reduced expression of FcγRIIB. Normal 
expression of FcγRIIB on plasma cells limits the longevity of plasma cells by inducing apoptosis 
through FcγRIIB cross-linking. Reduced expression of FcγRIIB on plasma cells from SLE patients 
and lupus-prone mice could avoid cell death of pathogenic plasma cells. Interestingly, plasma cells, 
from gp49B-deficient BXSB/Yaa mice, have slightly regained surface expression of FcγRIIB. From 
this aspect, it is possible that these two inhibitory receptors gp49B and FcγRIIB interact for 
maintenance the survival of pathogenic plasma cells. 
 
Conclusion 
gp49B serves as a pathogenic marker of autoreactive plasma cells in the newly-onset of SLE disease 
in BXSB/Yaa and RIIB−⁄−SLAM129 mice, although the underlying mechanism of gp49B on disease 
progression remains unknown. At the later stage of disease in RIIB−⁄−SLAM129 mice, it is possible that 
deprivation of gp49B amplifies the effect of tolerance loss originated from deficiency of FcγRIIB. 
